Exploring the Correlation of Ischemia-Modified Albumin, Lipid Profile, and Blood Pressure with Obesity Severity in COPD Patients: A Cross-Sectional Study at LUMHS Jamshoro
Keywords:
Ischemia Modified Albumin, Increased BP, Lipid Profile, Obesity, Predictive Marker, COPDAbstract
Objectives: This study aimed to examine the associations between ischemia-modified albumin (IMA), lipid profile, blood pressure, and obesity severity in Chronic Obstructive Pulmonary Disease (COPD) patients.
Methodology: Conducted at the Physiology Department of Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, this cross-sectional study involved 200 obese COPD patients, with an equal distribution of males and females. Following ethical approval from the ERC LUMHS, participants underwent physical examinations and provided blood samples for analysis of IMA and lipid profiles using an ELISA-based microplate assay kit. The study classified obesity into Class I, II, and III, and data were analyzed using SPSS version 23.0.
Results: The distribution of obesity among participants was 59.0% in Class I, 21.0% in Class II, and 20.0% in Class III. Mean IMA levels increased with obesity severity, showing significant variations across classes (p<0.05). HDL levels decreased with increasing obesity, but without statistical significance (p>0.05). Significant variations were observed in LDL levels, peaking in Class II. No significant differences were found in triglyceride (TAG) and cholesterol levels across obesity classes. Additionally, diastolic BP, HDL, LDL, TAG, cholesterol, and BMI showed significant variations with IMA status, but systolic BP did not (p=0.15). There were negative correlations between HDL and IMA levels, and positive correlations of BMI, diastolic BP, LDL, TAG, and cholesterol with IMA levels.
Conclusion: A significant correlation was observed between ischemia-modified albumin levels and the severity of obesity, lipid profiles and diastolic blood pressure among patients with chronic obstructive pulmonary disease. Monitoring IMA levels may be essential for assessing and managing cardiovascular risks in obese COPD patients, according to these findings.